{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:27:36Z","timestamp":1742387256034,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-024-05729-5","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T01:02:11Z","timestamp":1712970131000},"page":"2161-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture"],"prefix":"10.1007","volume":"103","author":[{"given":"Katsuyoshi","family":"Shimozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-5512","authenticated-orcid":false,"given":"Hiroshi","family":"Yagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kanezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"issue":"1","key":"5729_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3324\/haematol.2019.239160","volume":"106","author":"C Male","year":"2021","unstructured":"Male C, Andersson NG, Rafowicz A et al (2021) Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 106(1):123\u2013129. https:\/\/doi.org\/10.3324\/haematol.2019.239160","journal-title":"Haematologica"},{"issue":"2","key":"5729_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","volume":"109","author":"J Astermark","year":"2007","unstructured":"Astermark J, Donfield SM, DiMichele DM et al (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood 109(2):546\u2013551. https:\/\/doi.org\/10.1182\/blood-2006-04-017988","journal-title":"Blood"},{"issue":"1","key":"5729_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hae.13050","volume":"23","author":"Y Shinkoda","year":"2017","unstructured":"Shinkoda Y, Shirahata A, Fukutake K et al (2017) A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia 23(1):59\u201366. https:\/\/doi.org\/10.1111\/hae.13050","journal-title":"Haemophilia"},{"issue":"6","key":"5729_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/hae.12205","volume":"19","author":"A Shirahata","year":"2013","unstructured":"Shirahata A, Fukutake K, Takamatsu J et al (2013) A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics\/pharmacodynamics. Haemophilia 19(6):853\u2013860. https:\/\/doi.org\/10.1111\/hae.12205","journal-title":"Haemophilia"},{"issue":"2","key":"5729_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/hae.12024","volume":"19","author":"A Shirahata","year":"2013","unstructured":"Shirahata A, Fukutake K, Mimaya J et al (2013) Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors\u2013phase I trial: 2nd report. Haemophilia 19(2):330\u2013337. https:\/\/doi.org\/10.1111\/hae.12024","journal-title":"Haemophilia"},{"issue":"2","key":"5729_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/hae.14710","volume":"29","author":"M Sakai","year":"2023","unstructured":"Sakai M, Amano K, Chin M et al (2023) Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors. Haemophilia 29(2):456\u2013465. https:\/\/doi.org\/10.1111\/hae.14710","journal-title":"Haemophilia"},{"issue":"10","key":"5729_CR7","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","volume":"2","author":"LM Aledort","year":"2004","unstructured":"Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2(10):1700\u20131708. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00944.x","journal-title":"J Thromb Haemost"},{"issue":"19","key":"5729_CR8","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","volume":"363","author":"M Levi","year":"2010","unstructured":"Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomised clinical trials. N Engl J Med 363(19):1791\u20131800. https:\/\/doi.org\/10.1056\/NEJMoa1006221","journal-title":"N Engl J Med"},{"issue":"8","key":"5729_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/MBC.0000000000000851","volume":"30","author":"R Shirayama","year":"2019","unstructured":"Shirayama R, Takedani H, Chikasawa Y et al (2019) Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa\/FX (byclot) in haemophilia patients with high-responding type inhibitors. Blood Coagul Fibrinolysis 30(8):385\u2013392. https:\/\/doi.org\/10.1097\/MBC.0000000000000851","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"5729_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejmoa2216455","volume":"389","author":"T Matsushita","year":"2023","unstructured":"Matsushita T, Shapiro A, Abraham A et al (2023) Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med 389(9):783\u2013794. https:\/\/doi.org\/10.1056\/nejmoa2216455","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05729-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:07:02Z","timestamp":1715580422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05729-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5729"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05729-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"30 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Declaration of Helsinki and its later amendments (or comparable ethical standards). The clinical trials in which the patient was enrolled were approved by the Institutional Review Board of the Nihon University Itabashi Hospital (3107\u2009\u2212\u20091542, 3206\u2009\u2212\u20091563). Consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"H.Y. has received speaker fees from KM Biologics. I.M. received speaker fees from Novo Nordisk. The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}